Ardelyx (ARDX) Prices 20M Share Upized Offering at $6.25/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Ardelyx (ARDX) Announces Proposed $80M Public Offering of Common Stock
December 4, 2019 4:57 PM ESTArdelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that it has commenced an underwritten public offering of up to $80,000,000 of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Ardelyx. In addition,... More
Ardelyx, Inc (ARDX) PT Raised to $10 at SVB Leerink
December 3, 2019 1:14 PM ESTSVB Leerink analyst Ami Fadia raised the price target on Ardelyx, Inc (NASDAQ: ARDX) to $10.00 (from $9.00) while maintaining a Outperform rating.
... MoreArdelyx (ARDX) to Resume Trading at 7:55 am
December 3, 2019 7:37 AM ESTArdelyx (NASDAQ: ARDX) to Resume Trading at 7:55 am
... MoreArdelyx (ARDX) Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis Meets Primary Endpoint
December 3, 2019 7:26 AM ESTArdelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today reported positive topline results from PHREEDOM, a long-term Phase 3 study evaluating the efficacy and safety of tenapanor as monotherapy for the treatment of... More
Ardelyx (ARDX) Halted, News Pending
December 3, 2019 7:22 AM ESTArdelyx (NASDAQ: ARDX) Halted, News Pending
... More